{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:16:01Z","timestamp":1790615761982,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass spectrometry analysis of HLA class I-bound peptides from 35 PDAC patient tumors. This identified a shared HLA-A*0101 restricted peptide derived from co-transcriptional activator Vestigial-like 1 (VGLL1) as a putative TAA demonstrating overexpression in multiple tumor types and low or absent expression in essential normal tissues. Here we show that VGLL1-specific CTLs expanded from the blood of a PDAC patient could recognize and kill in an antigen-specific manner a majority of HLA-A*0101 allogeneic tumor cell lines derived not only from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast cancers. Gene expression profiling reveals VGLL1 as a member of a unique group of cancer-placenta antigens (CPA) that may constitute immunotherapeutic targets for patients with multiple cancer types.<\/jats:p>","DOI":"10.1038\/s41467-020-19141-w","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T06:04:15Z","timestamp":1603260255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers"],"prefix":"10.1038","volume":"11","author":[{"given":"Sherille D.","family":"Bradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad H.","family":"Talukder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Tiriac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-2861","authenticated-orcid":false,"given":"Kyle R.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Katailiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-7203","authenticated-orcid":false,"given":"Heather M.","family":"Sonnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenge","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bih-Fang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-7774","authenticated-orcid":false,"given":"Philip L.","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6102-4925","authenticated-orcid":false,"given":"Mark","family":"Hurd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3316-0468","authenticated-orcid":false,"given":"Christine B.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Tuveson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6102-7843","authenticated-orcid":false,"given":"David","family":"Hawke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-9978","authenticated-orcid":false,"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-6170","authenticated-orcid":false,"given":"Jason","family":"Roszik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-7307","authenticated-orcid":false,"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-7461","authenticated-orcid":false,"given":"Gregory","family":"Liz\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"19141_CR1","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1002\/cncr.30342","volume":"122","author":"AM Varghese","year":"2016","unstructured":"Varghese, A. M., Lowery, M. A., Yu, K. H. & O\u2019Reilly, E. M. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 122, 3765\u20133775 (2016).","journal-title":"Cancer"},{"key":"19141_CR2","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan, A. et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 24, 4846\u20134861 (2018).","journal-title":"World J. Gastroenterol."},{"key":"19141_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/MPA.0000000000000368","volume":"44","author":"ST Chari","year":"2015","unstructured":"Chari, S. T. et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas 44, 693\u2013712 (2015).","journal-title":"Pancreas"},{"key":"19141_CR4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.7150\/jca.14922","volume":"7","author":"K Polireddy","year":"2016","unstructured":"Polireddy, K. & Chen, Q. Cancer of the pancreas: molecular pathways and current advancement in treatment. J. Cancer 7, 1497\u20131514 (2016).","journal-title":"J. Cancer"},{"key":"19141_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"19141_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","volume":"16","author":"O Strobel","year":"2019","unstructured":"Strobel, O., Neoptolemos, J., Jager, D. & Buchler, M. W. Optimizing the outcomes of pancreatic cancer surgery. Nat. Rev. Clin. Oncol. 16, 11\u201326 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"19141_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-med-112311-083918","volume":"64","author":"G Lizee","year":"2013","unstructured":"Lizee, G. et al. Harnessing the power of the immune system to target cancer. Annu Rev. Med 64, 71\u201390 (2013).","journal-title":"Annu Rev. Med"},{"key":"19141_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Disco. 8, 1069\u20131086 (2018).","journal-title":"Cancer Disco."},{"key":"19141_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"19141_CR10","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","volume":"23","author":"ME Dudley","year":"2005","unstructured":"Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346\u20132357 (2005).","journal-title":"J. Clin. Oncol."},{"key":"19141_CR11","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","volume":"18","author":"LG Radvanyi","year":"2012","unstructured":"Radvanyi, L. G. et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18, 6758\u20136770 (2012).","journal-title":"Clin. Cancer Res."},{"key":"19141_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387\u20131390 (2015).","journal-title":"Science"},{"key":"19141_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"19141_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs, C. S. & Rosenberg, S. A. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257, 56\u201371 (2014).","journal-title":"Immunol. Rev."},{"key":"19141_CR15","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","volume":"34","author":"AG Chapuis","year":"2016","unstructured":"Chapuis, A. G. et al. T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. J. Clin. Oncol. 34, 3787\u20133795 (2016).","journal-title":"J. Clin. Oncol."},{"key":"19141_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1084\/jem.20152021","volume":"213","author":"AG Chapuis","year":"2016","unstructured":"Chapuis, A. G. et al. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J. Exp. Med. 213, 1133\u20131139 (2016).","journal-title":"J. Exp. Med."},{"key":"19141_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"19141_CR18","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara, I. et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 130, 1985\u20131994 (2017).","journal-title":"Blood"},{"key":"19141_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"19141_CR20","doi-asserted-by":"publisher","first-page":"175883591881628","DOI":"10.1177\/1758835918816281","volume":"10","author":"K Young","year":"2018","unstructured":"Young, K., Hughes, D. J., Cunningham, D. & Starling, N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther. Adv. Med. Oncol. 10, 1758835918816281 (2018).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"19141_CR21","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A. & Algul, H. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front Immunol. 9, 1878 (2018).","journal-title":"Front Immunol."},{"key":"19141_CR22","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"19141_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512\u2013516 (2017).","journal-title":"Nature"},{"key":"19141_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"19141_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fimmu.2018.01044","volume":"9","author":"ED Foucher","year":"2018","unstructured":"Foucher, E. D. et al. Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment. Front Immunol. 9, 1044 (2018).","journal-title":"Front Immunol."},{"key":"19141_CR26","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"19141_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155, 29\u201332 (2018).","journal-title":"Gastroenterology"},{"key":"19141_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2015.09.022","volume":"28","author":"IM Stromnes","year":"2015","unstructured":"Stromnes, I. M. et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28, 638\u2013652 (2015).","journal-title":"Cancer Cell"},{"key":"19141_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru, M., O\u2019Cearbhaill, R., Pendharkar, S., Spriggs, D. R. & Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).","journal-title":"J. Transl. Med."},{"key":"19141_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"19141_CR31","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","volume":"9","author":"M Akce","year":"2018","unstructured":"Akce, M., Zaidi, M. Y., Waller, E. K., El-Rayes, B. F. & Lesinski, G. B. The potential of CAR T cell therapy in pancreatic cancer. Front Immunol. 9, 2166 (2018).","journal-title":"Front Immunol."},{"key":"19141_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","volume":"4","author":"AH Morrison","year":"2018","unstructured":"Morrison, A. H., Byrne, K. T. & Vonderheide, R. H. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 4, 418\u2013428 (2018).","journal-title":"Trends Cancer"},{"key":"19141_CR33","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.18632\/oncotarget.24483","volume":"9","author":"RA Wolff","year":"2018","unstructured":"Wolff, R. A. et al. Dynamic changes during the treatment of pancreatic cancer. Oncotarget 9, 14764\u201314790 (2018).","journal-title":"Oncotarget"},{"key":"19141_CR34","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"19141_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0288-x","volume":"8","author":"M Nielsen","year":"2016","unstructured":"Nielsen, M. & Andreatta, M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 8, 33 (2016).","journal-title":"Genome Med."},{"key":"19141_CR36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"19141_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133\u2013151 (2013).","journal-title":"J. Immunother."},{"key":"19141_CR38","doi-asserted-by":"publisher","first-page":"E9942","DOI":"10.1073\/pnas.1707658114","volume":"114","author":"H Schuster","year":"2017","unstructured":"Schuster, H. et al. The immunopeptidomic landscape of ovarian carcinomas. Proc. Natl Acad. Sci. USA 114, E9942\u2013E9951 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"19141_CR39","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1242\/dev.126.21.4807","volume":"126","author":"P Vaudin","year":"1999","unstructured":"Vaudin, P., Delanoue, R., Davidson, I., Silber, J. & Zider, A. TONDU (TDU), a novel human protein related to the product of vestigial (vg) gene of Drosophila melanogaster interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. Development 126, 4807\u20134816 (1999).","journal-title":"Development"},{"key":"19141_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00427-016-0546-3","volume":"226","author":"E Simon","year":"2016","unstructured":"Simon, E., Faucheux, C., Zider, A., Theze, N. & Thiebaud, P. From vestigial to vestigial-like: the Drosophila gene that has taken wing. Dev. Genes Evol. 226, 297\u2013315 (2016).","journal-title":"Dev. Genes Evol."},{"key":"19141_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/ERC-13-0485","volume":"21","author":"MA Castilla","year":"2014","unstructured":"Castilla, M. A. et al. VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. Endocr. Relat. Cancer 21, 587\u2013599 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"19141_CR42","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1097\/PAS.0b013e3182159dec","volume":"35","author":"L Cheng","year":"2011","unstructured":"Cheng, L. et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am. J. Surg. Pathol. 35, e34\u2013e46 (2011).","journal-title":"Am. J. Surg. Pathol."},{"key":"19141_CR43","doi-asserted-by":"publisher","unstructured":"Soncin, F. et al. Comparative analysis of mouse and human placentae across gestation reveals species-specific regulators of placental development. Development 145, https:\/\/doi.org\/10.1242\/dev.156273 (2018).","DOI":"10.1242\/dev.156273"},{"key":"19141_CR44","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/ijc.23341","volume":"122","author":"XY Dong","year":"2008","unstructured":"Dong, X. Y. et al. Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. Int J. Cancer 122, 2038\u20132043 (2008).","journal-title":"Int J. Cancer"},{"key":"19141_CR45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ags3.12176","volume":"2","author":"RJ Torphy","year":"2018","unstructured":"Torphy, R. J., Zhu, Y. & Schulick, R. D. Immunotherapy for pancreatic cancer: barriers and breakthroughs. Ann. Gastroenterol. Surg. 2, 274\u2013281 (2018).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"19141_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","volume":"4","author":"QJ Wang","year":"2016","unstructured":"Wang, Q. J. et al. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol. Res 4, 204\u2013214 (2016).","journal-title":"Cancer Immunol. Res"},{"key":"19141_CR47","doi-asserted-by":"publisher","first-page":"75 e71-10","DOI":"10.1016\/j.ajog.2008.08.014","volume":"200","author":"S Bellone","year":"2009","unstructured":"Bellone, S. et al. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Am. J. Obstet. Gynecol. 200, 75 e71-10 (2009).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"19141_CR48","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14728222.2018.1498845","volume":"22","author":"A Aithal","year":"2018","unstructured":"Aithal, A. et al. MUC16 as a novel target for cancer therapy. Expert Opin. Ther. Targets 22, 675\u2013686 (2018).","journal-title":"Expert Opin. Ther. Targets"},{"key":"19141_CR49","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","volume":"43","author":"FF Gonzalez-Galarza","year":"2015","unstructured":"Gonzalez-Galarza, F. F. et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 43, D784\u2013D788 (2015).","journal-title":"Nucleic Acids Res."},{"key":"19141_CR50","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"19141_CR51","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.str.2012.04.004","volume":"20","author":"AV Pobbati","year":"2012","unstructured":"Pobbati, A. V., Chan, S. W., Lee, I., Song, H. & Hong, W. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure 20, 1135\u20131140 (2012).","journal-title":"Structure"},{"key":"19141_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/cbic.201300715","volume":"15","author":"Y Mesrouze","year":"2014","unstructured":"Mesrouze, Y. et al. The surprising features of the TEAD4-Vgll1 protein-protein interaction. Chembiochem 15, 537\u2013542 (2014).","journal-title":"Chembiochem"},{"key":"19141_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0086-y","author":"IM Moya","year":"2018","unstructured":"Moya, I. M. & Halder, G. Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev. Mol. Cell Biol. https:\/\/doi.org\/10.1038\/s41580-018-0086-y (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"19141_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0882-1","volume":"17","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. The role of YAP\/TAZ activity in cancer metabolic reprogramming. Mol. Cancer 17, 134 (2018).","journal-title":"Mol. Cancer"},{"key":"19141_CR55","doi-asserted-by":"publisher","unstructured":"Zhou, Y. et al. The TEAD family and its oncogenic role in promoting tumorigenesis. Int. J. Mol. Sci. 17, https:\/\/doi.org\/10.3390\/ijms17010138 (2016).","DOI":"10.3390\/ijms17010138"},{"key":"19141_CR56","first-page":"124","volume":"38","author":"J Chen","year":"2006","unstructured":"Chen, J. et al. PLAC1\/CP1 gene expression and autologous humoral immunity in gastric cancer patients. Beijing Da Xue Xue Bao Yi Xue Ban. 38, 124\u2013127 (2006).","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban."},{"key":"19141_CR57","first-page":"18","volume":"7","author":"WA Silva Jr.","year":"2007","unstructured":"Silva, W. A. Jr. et al. PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun. 7, 18 (2007).","journal-title":"Cancer Immun."},{"key":"19141_CR58","first-page":"5924","volume":"15","author":"Q Li","year":"2018","unstructured":"Li, Q. et al. PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer. Oncol. Lett. 15, 5924\u20135932 (2018).","journal-title":"Oncol. Lett."},{"key":"19141_CR59","doi-asserted-by":"crossref","first-page":"101042831769592","DOI":"10.1177\/1010428317695928","volume":"39","author":"R Shi","year":"2017","unstructured":"Shi, R. et al. Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell lung cancer. Tumour Biol. 39, 1010428317695928 (2017).","journal-title":"Tumour Biol."},{"key":"19141_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0647-2","volume":"16","author":"Y Zhou","year":"2017","unstructured":"Zhou, Y. et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol. Cancer 16, 77 (2017).","journal-title":"Mol. Cancer"},{"key":"19141_CR61","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/2326-6066.CIR-17-0051","volume":"5","author":"J Park","year":"2017","unstructured":"Park, J. et al. SLC45A2: a melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunol. Res. 5, 618\u2013629 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"19141_CR62","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/2326-6066.CIR-15-0030","volume":"3","author":"SD Bradley","year":"2015","unstructured":"Bradley, S. D. et al. BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol. Res. 3, 602\u2013609 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"19141_CR63","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B. J. et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).","journal-title":"Sci. Transl. Med."},{"key":"19141_CR64","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.4049\/jimmunol.175.4.2261","volume":"175","author":"Y Li","year":"2005","unstructured":"Li, Y., Bleakley, M. & Yee, C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175, 2261\u20132269 (2005).","journal-title":"J. Immunol."},{"key":"19141_CR65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1182\/blood-2007-05-089375","volume":"111","author":"Y Li","year":"2008","unstructured":"Li, Y. & Yee, C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111, 229\u2013235 (2008).","journal-title":"Blood"},{"key":"19141_CR66","doi-asserted-by":"publisher","first-page":"174ra127","DOI":"10.1126\/scitranslmed.3004916","volume":"5","author":"AG Chapuis","year":"2013","unstructured":"Chapuis, A. G. et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 5, 174ra127 (2013).","journal-title":"Sci. Transl. Med."},{"key":"19141_CR67","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1158\/2326-6066.CIR-19-0619","volume":"8","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8(+) T cells to memory T cells. Cancer Immunol. Res. 8, 794\u2013805 (2020).","journal-title":"Cancer Immunol. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19141-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:30:00Z","timestamp":1670272200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19141-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["19141"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-19141-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"31 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5332"}}